Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 6, 2000, Pages 585-589

  Barlow, Hannah C ^a   Bowman, Karen J ^b   Curtin, Nicola J ^b   Calvert, A Hilary ^b   Golding, Bernard T ^a   Huang, Bing ^a   Loughlin, Peter J ^a   Newell, David R ^b   Smith, Peter G ^b   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4,8 DIBENZYLAMINOPYRIMIDOPYRIMIDINE; ALPHA1 GLYCOPROTEIN; DIPYRIDAMOLE; NUCLEOSIDE; PYRIMIDINE DERIVATIVE; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION (PARAMETERS); DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; LEUKEMIA CELL LINE; LEUKEMIA L 1210; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PYRIMIDINE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CHEMISTRY, PHYSICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA L1210; NUCLEOSIDES; OROSOMUCOID; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0034689405     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00053-6     Document Type: Article

References (22)

1. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.-B., Wilke H., Seeber S. J. Clin. Oncol. 15:1997;389.
2. Jackman A.L., Calvert A.H. Annals of Oncology. 6:1995;871.
3. Jackman A.L., Taylor G.A., Calvert A.H., Harrap K.R. Biochem. Pharmacol. 33:1984;3269.
4. Fox M., Boyle J.M., Kinsella A.R. Br. J. Cancer. 64:1991;428.
5. Belt J.A., Marina N.M., Phelps D.A., Crawford C.R. Advan. Enzyme Regul. 33:1993;235.
6. Goel, R.; Howell, S.B. In New Drugs, Concepts and Results in Cancer Chemotherapy; Muggia, F. M., Ed.; Kluwer Academic Press: Boston, MA,1992; pp 19.
7. Turner R.N., Aherne G.W., Curtin N.J. Br. J. Cancer. 76:1997;1300.
8. Smith P.G., Marshman E., Calvert A.H., Newell D.R., Curtin N.J. Semin. Oncol. 26:1999;63.
9. Plagemann P.G.W., Wohlhueter R.M., Woffendin C. Biochim. Biophys. Acta. 947:1988;405.
10. Buolamwini J.K. Current Med. Chem. 4:1997;35.
11. Wadler S., Subar M., Green M.D., Wiernik P.H., Muggia F.M. Cancer Treatment Reports. 71:1987;821.
12. Schmoll H.-J., Harstrick A., Köhne-Wömpner C.-H., Schöber C., Wilke H., Poliwoda H. Cancer Treatment Reviews. 17:1990;57.
13. Turner G.A., Skillen A.W., Buamah P., Guthrie D., Welsh J., Harrison J., Kowalski A. J. Clin. Pathol. 38:1985;588.
14. Kremer J.M.H., Wilting J., Janssen L.H.M. Pharmacol. Revs. 40:1988;1.
15. Curtin N.J., Newell D.R., Harris A.L. Biochem. Pharmacol. 38:1989;3281.
16. Budd G.T., Jayaraj A., Grabowski D., Adelstein D., Bauer L., Boyett J., Bukowski R., Murthy S., Weick J. Cancer Res. 50:1990;7206.
17. Thomae, K.G. 1959, Brit. Pat. 807826. (Chem. Abstr. 1959, 53, 12317e).
18. Thomae, K.G. 1963, Ger. Pat. 1151806. (Chem. Abstr. 1964, 60, 2974a).
19. +, 100%).
20. 3 solution (20 mL), and stirred for 12 h.
21. Curtin N.J., Bowman K.J., Turner R.N., Huang B., Loughlin P.J., Calvert A.H., Golding B.T., Griffin R.J., Newell D.R. Br. J. Cancer. 80:1999;1738.
22. 6 cells was followed at 2 s intervals over a 12 s time course in the presence or absence of inhibitor in 1 or 5% (v/v) DMSO. In experiments to determine the effect of AGP, the uptake of thymidine was also measured in the presence of 5 mg/mL human AGP.